IMPACT OF COVID 19 IN MERGER & ACQUISITION OF INDIAN PHARMA COMPANY

The impact of COVID-19 on pharmaceuticals M&A, even as the sector continues to work overtime to find a preventive (and possibly curative) solution to the pandemic and restore the ‘health currency' necessary to drive the broader global economy, challenging issues to tackle and huge network of smart people are working day and night to come out this situation. This pandemic opens many avenues of opportunities and growth though innovation is fragmented idea in this new topic. The biopharma are facing very challenging environment to adopt the idea of thrive in era of covid 19.Some big pharma come together to join the hands for vaccination. M&A is a labour-intensive activity that requires a lot of hard work, evaluation and collaborative effort across several organisations, multiple negotiation meetings, site visits to assess physical assets, evaluating markets, sifting through millions of documents, and so on. Industry participants have adjusted to the reality of simulation based ideas and webinars. But the complete standstill of the first few months and the need for physical diligence for a few critical parts have caused the timing shift. To bring back the life in the normal course it is necessary to make vaccine of covid 19 to reduce the effect. New investors are accelerating their pace in merger and acquisition in pharmaceutical industry. Lots of webinars are going on this topic to combat the situation. To achieve the concept of health currency we need to work hard including researchers, scientists, pharma companies' academicians etc.